Hanne Hawle

1.1k total citations
24 papers, 618 citations indexed

About

Hanne Hawle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Hanne Hawle has authored 24 papers receiving a total of 618 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 9 papers in Pulmonary and Respiratory Medicine and 6 papers in Cancer Research. Recurrent topics in Hanne Hawle's work include Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Hanne Hawle is often cited by papers focused on Advanced Breast Cancer Therapies (6 papers), Breast Cancer Treatment Studies (5 papers) and HER2/EGFR in Cancer Research (5 papers). Hanne Hawle collaborates with scholars based in Switzerland, Germany and France. Hanne Hawle's co-authors include Beat Thürlimann, Robert Paridaens, Aron Goldhirsch, Stefanie Hayoz, Thomas Ruhstaller, Lucien Perey, Khalil Zaman, Dieter Köberle, D. Dietrich and Maryse Fiche and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Hanne Hawle

23 papers receiving 607 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Hanne Hawle Switzerland	12	318	163	159	154	146	24	618
В. С. Медведев Russia	4	397 1.2×	207 1.3×	118 0.7×	242 1.6×	103 0.7×	11	950
Jørn Andersen Denmark	20	461 1.4×	165 1.0×	181 1.1×	107 0.7×	285 2.0×	36	1.0k
J P Basuyau France	15	226 0.7×	107 0.7×	66 0.4×	142 0.9×	136 0.9×	33	618
D F Hayes United States	8	464 1.5×	92 0.6×	234 1.5×	152 1.0×	329 2.3×	12	765
Keiichi Kinowaki Japan	11	141 0.4×	142 0.9×	22 0.1×	97 0.6×	46 0.3×	99	479
J. Carmichael United Kingdom	16	635 2.0×	299 1.8×	188 1.2×	134 0.9×	178 1.2×	24	987
Annamaria Guazzi Italy	15	311 1.0×	144 0.9×	41 0.3×	215 1.4×	168 1.2×	35	597
S. Vukelja United States	10	707 2.2×	179 1.1×	370 2.3×	82 0.5×	73 0.5×	30	911
Bozena Möller Sweden	9	203 0.6×	93 0.6×	90 0.6×	41 0.3×	26 0.2×	12	962
R. Knight United Kingdom	15	367 1.2×	66 0.4×	77 0.5×	134 0.9×	275 1.9×	32	642

Countries citing papers authored by Hanne Hawle

Since Specialization

Citations

This map shows the geographic impact of Hanne Hawle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hanne Hawle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hanne Hawle more than expected).

Fields of papers citing papers by Hanne Hawle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hanne Hawle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hanne Hawle. The network helps show where Hanne Hawle may publish in the future.

Co-authorship network of co-authors of Hanne Hawle

This figure shows the co-authorship network connecting the top 25 collaborators of Hanne Hawle. A scholar is included among the top collaborators of Hanne Hawle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hanne Hawle. Hanne Hawle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fehr, Martin, Hanne Hawle, Stefanie Hayoz, et al.. (2020). High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08. BMC Cancer. 20(1). 166–166. 4 indexed citations

Menter, Thomas, Alexandar Tzankov, Emanuele Zucca, et al.. (2020). Prognostic implications of the microenvironment for follicular lymphoma under immunomodulation therapy. British Journal of Haematology. 189(4). 707–717. 16 indexed citations

Varga, Zsuzsanna, Qiyu Li, Wolfram Jochum, et al.. (2019). Ki-67 assessment in early breast cancer: SAKK28/12 validation study on the IBCSG VIII and IBCSG IX cohort. Scientific Reports. 9(1). 13534–13534. 10 indexed citations

Vetter, Marcus, Karin Rothgiesser, Hanne Hawle, et al.. (2019). SAKK 21/12: A stratified, multicenter phase II trial of transdermal CR1447 in endocrine responsive-HER2 negative and triple negative-androgen receptor positive metastatic or locally advanced breast cancer. Annals of Oncology. 30. iii52–iii52. 2 indexed citations

Panje, Cédric, Stefanie Hayoz, Vickie E. Baracos, et al.. (2019). Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy. Radiation Oncology. 14(1). 166–166. 33 indexed citations

Moos, Roger von, Hanne Hawle, Stefanie Hayoz, et al.. (2018). Incidence of hypocalcemia in a non-inferiority phase III trial assessing prevention of symptomatic skeletal events (SSE) with denosumab (DN) administered every 4 weeks (q4w) versus every 12 weeks (q12w): SAKK 96/12 (REDUSE). Annals of Oncology. 29. viii609–viii610. 4 indexed citations

Henke, Guido, Michael Knauer, Karin Ribi, et al.. (2018). Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial. Trials. 19(1). 667–667. 83 indexed citations

Ruhstaller, Thomas, Peter Thuss‐Patience, Stefanie Hayoz, et al.. (2018). Neoadjuvant chemotherapy followed by chemoradiation and surgery with and without cetuximab in patients with resectable esophageal cancer: a randomized, open-label, phase III trial (SAKK 75/08). Annals of Oncology. 29(6). 1386–1393. 76 indexed citations

Huober, Jens, Patrik Weder, Corinne Veyret, et al.. (2018). PERNETTA: A non-comparative randomized open label phase II trial of pertuzumab (P) + trastuzumab (T) with or without chemotherapy both followed by T-DM1 in case of progression, in patients with HER2-positive metastatic breast cancer (MBC): (SAKK 22/10 / UNICANCER UC-0140/1207). Annals of Oncology. 29. viii93–viii93. 5 indexed citations

10.

Ruhstaller, Thomas, Peter Thuss‐Patience, Stefanie Hayoz, et al.. (2017). Intergroup phase III trial of neo-adjuvant chemotherapy, followed by chemoradiation and surgery with and without cetuximab in locally advanced esophageal carcinoma: First results from the SAKK 75/08 trial.. Journal of Clinical Oncology. 35(15_suppl). 4019–4019. 4 indexed citations

11.

Driessen, Christoph, Rouven Müller, Urban Novak, et al.. (2016). The HIV Protease Inhibitor Nelfinavir in Combination with Bortezomib and Dexamethasone (NVd) Has Excellent Activity in Patients with Advanced, Proteasome Inhibitor-Refractory Multiple Myeloma: A Multicenter Phase II Trial (SAKK 39/13). Blood. 128(22). 487–487. 13 indexed citations

12.

Zaman, Khalil, Christoph Mamot, Christoph Rochlitz, et al.. (2015). Fulvestrant with or without selumetinib, a MEK 1/2 inhibitor, in breast cancer progressing after aromatase inhibitor therapy: A multicentre randomised placebo-controlled double-blind phase II trial, SAKK 21/08. European Journal of Cancer. 51(10). 1212–1220. 43 indexed citations

13.

Driessen, Christoph, Marianne Kraus, Markus Joerger, et al.. (2015). Treatment with the HIV protease inhibitor nelfinavir triggers the unfolded protein response and may overcome proteasome inhibitor resistance of multiple myeloma in combination with bortezomib: a phase I trial (SAKK 65/08). Haematologica. 101(3). 346–355. 47 indexed citations

14.

Huober, J., Patrik Weder, Epie Boven, et al.. (2013). Abstract OT1-1-05: Pernetta: A randomized phase II trial of pertuzumab + trastuzumab with or without chemotherapy, both followed by T-DM1 at progression, in patients with HER2-positive metastatic breast cancer - SAKK 22/10 / UNICANCER UC-0140/1207. Cancer Research. 73(24_Supplement). OT1–1.

15.

Rabaglio, Manuela, Zijie Sun, Karen N. Price, et al.. (2009). Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial. Annals of Oncology. 20(9). 1489–1498. 133 indexed citations

16.

Wildhardt, G., et al.. (2009). A monoallelic double mutation as a cause for TNF receptor-associated periodic fever syndrome. Rheumatology International. 30(6). 805–809. 3 indexed citations

17.

Hawle, Hanne, et al.. (2008). Familiäres Mittelmeerfieber in einer deutschen Familie. DMW - Deutsche Medizinische Wochenschrift. 114(17). 665–668. 1 indexed citations

18.

Perey, Lucien, Robert Paridaens, Hanne Hawle, et al.. (2006). Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Annals of Oncology. 18(1). 64–69. 103 indexed citations

19.

Lugli, Alessandro, Sergio Cogliatti, Aloïs Gratwohl, et al.. (2004). Proposal of a morphologic bone marrow response score for imatinib mesylate treatment in chronic myelogenous leukemia. Human Pathology. 36(1). 91–100. 12 indexed citations

20.

Hawle, Hanne, et al.. (1989). [Screening for colorectal neoplasms: comparison of Hemdetect and Haemoccult].. PubMed. 27(10). 611–3. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact